CO4960649A1 - Esmalte para unas que contiene al menos un glucocorticoide y procedimiento de fabricacion - Google Patents

Esmalte para unas que contiene al menos un glucocorticoide y procedimiento de fabricacion

Info

Publication number
CO4960649A1
CO4960649A1 CO98046943A CO98046943A CO4960649A1 CO 4960649 A1 CO4960649 A1 CO 4960649A1 CO 98046943 A CO98046943 A CO 98046943A CO 98046943 A CO98046943 A CO 98046943A CO 4960649 A1 CO4960649 A1 CO 4960649A1
Authority
CO
Colombia
Prior art keywords
nail polish
fluonater
glucocorticoid
dipropionate
active substance
Prior art date
Application number
CO98046943A
Other languages
English (en)
Inventor
Bohn Manfred
Karl Theodor Kraemer
Original Assignee
Aventis Pharma Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aventis Pharma Gmbh filed Critical Aventis Pharma Gmbh
Publication of CO4960649A1 publication Critical patent/CO4960649A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q3/00—Manicure or pedicure preparations
    • A61Q3/02—Nail coatings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/63—Steroids; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/72—Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds
    • A61K8/81—Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds obtained by reactions involving only carbon-to-carbon unsaturated bonds
    • A61K8/8141—Compositions of homopolymers or copolymers of compounds having one or more unsaturated aliphatic radicals, each having only one carbon-to-carbon double bond, and at least one being terminated by only one carboxyl radical, or of salts, anhydrides, esters, amides, imides or nitriles thereof; Compositions of derivatives of such polymers
    • A61K8/8152—Homopolymers or copolymers of esters, e.g. (meth)acrylic acid esters; Compositions of derivatives of such polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7015—Drug-containing film-forming compositions, e.g. spray-on
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Birds (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Dermatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Cosmetics (AREA)
  • Steroid Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Finger-Pressure Massage (AREA)
  • Chemical And Physical Treatments For Wood And The Like (AREA)
  • Orthopedics, Nursing, And Contraception (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Esmalte para unas con actividad antipsoriásica. Esmalte para unas que contiene al menos un glucocorticoide, al menos un disolvente fisiológicamente inocuo y al menos un formador de película insoluble en agua. El esmalte para uñas es adecuado para el tratamiento de la psoriasis ungular. Esmalte para unas de acuerdo con la reivindicación 1, caracterizado porque como glucocorticoide contiene dipropionato de alclometasona, amcinonida, dipropionato de beclometasona, bendacort, benzoato de betametasona, dipropionato de betametasona, valerato de betametasona, budesonida, clorquinaldol, clioquinol, propionato de clobetasol, butirato de clobetasona, desonida, desoximetasona, dexametasona, diclorisona, diacetato de diflorasona, valerato de diflucortolona, difluprednato, fluazacort, acetónido de flucinolona, acetónido de fluclorolona, fludroxicortida, pivalato de flumetasona, acetónidos de fluocinolona, fluocinoida, fluocortolona, fluormetolona, flupamesona, fluprednideno, acetato de fluprednideno, flurandenolida, halcinonida, halometasona, hidrocortamato, butirato de hidrocortisona, aceponato de metilprednisolona, furoato de mometasona, prednicarbato, prednisolona, prednisona, tixocortol, acetonido de triamcinolona. Esmalte para uñas de acuerdo con una o varias de las reivindicaciones 1 y 2, caracterizado porque contiene como sustancia activa propionato de clobetasol, desoximetasona, dipropionato de betametasona, prednicarbato o halcinonida. Esmalte para uñas de acuerdo con una o varias de las reivindicaciones 1 a 3, caracterizado porque contiene la sustancia activa o sustancias activas en una concentración global de 0,5% a 20%, referida al peso total de la formulación. Esmalte para uñas de acuerdo con una o varias de las reivindicaciones 1 a 4, caracterizado porque contiene la sustancia activa o sustancias activas en una concentración global de 2% a 15%, referida al peso total de la formulación.
CO98046943A 1997-08-21 1998-08-18 Esmalte para unas que contiene al menos un glucocorticoide y procedimiento de fabricacion CO4960649A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE19736112 1997-08-21

Publications (1)

Publication Number Publication Date
CO4960649A1 true CO4960649A1 (es) 2000-09-25

Family

ID=7839551

Family Applications (1)

Application Number Title Priority Date Filing Date
CO98046943A CO4960649A1 (es) 1997-08-21 1998-08-18 Esmalte para unas que contiene al menos un glucocorticoide y procedimiento de fabricacion

Country Status (36)

Country Link
US (3) US6352686B2 (es)
EP (1) EP0913154B1 (es)
JP (1) JPH11130679A (es)
KR (1) KR100610517B1 (es)
CN (1) CN1155386C (es)
AR (1) AR015933A1 (es)
AT (1) ATE227993T1 (es)
AU (1) AU740615B2 (es)
BG (1) BG63270B1 (es)
BR (1) BR9803756A (es)
CA (1) CA2245637C (es)
CO (1) CO4960649A1 (es)
CZ (1) CZ292344B6 (es)
DE (1) DE59806343D1 (es)
DK (1) DK0913154T3 (es)
ES (1) ES2186952T3 (es)
HK (1) HK1018214A1 (es)
HR (1) HRP980458B1 (es)
HU (1) HUP9801898A3 (es)
ID (1) ID20731A (es)
IL (1) IL125854A (es)
MY (1) MY128558A (es)
NO (1) NO319391B1 (es)
NZ (1) NZ331443A (es)
PL (1) PL192342B1 (es)
PT (1) PT913154E (es)
RO (1) RO118174B1 (es)
RU (1) RU2210354C2 (es)
SG (1) SG68072A1 (es)
SI (1) SI0913154T1 (es)
SK (1) SK284218B6 (es)
TR (1) TR199801609A3 (es)
TW (1) TW590776B (es)
UA (1) UA51693C2 (es)
YU (1) YU49492B (es)
ZA (1) ZA987531B (es)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RO118174B1 (ro) * 1997-08-21 2003-03-28 Aventis Pharma Deutschland Gmbh Lac de unghii şi utilizarea acestuia
CA2431236A1 (en) * 2001-01-09 2002-07-18 Israel Dvoretzky Therapeutic film forming composition and treatment system
FR2830449B1 (fr) * 2001-10-05 2004-04-23 Fabre Pierre Dermo Cosmetique Utilisation du tazarotene pour la preparation d'un vernis a ongles pour le traitement et/ou la prevention du psoriasis et un vernis a ongles le contenant
FR2835180B1 (fr) * 2002-01-30 2004-04-09 Fiabila Vernis a ongles multiphase
AU2002950506A0 (en) * 2002-07-31 2002-09-12 Soltec Research Pty Ltd Percutaneous delivery system
EP1854466A1 (en) * 2002-12-17 2007-11-14 Galderma Research & Development, S.N.C. Pharmaceutical composition comprising a combination of calcitriol and clobetasol propionate
DE60316724T2 (de) * 2002-12-17 2008-07-17 Galderma S.A. Pharmazeutische zusammensetzung enthaltend calcitriol und clobetasolpropionat
FR2848454B1 (fr) * 2002-12-17 2007-03-30 Galderma Res & Dev Composition pharmaceutique comprenant une association de calcitriol et d'un corticosteroide
US7238533B1 (en) * 2003-07-22 2007-07-03 Ronald Legge Personal illicit drug detection method
FR2871699A1 (fr) * 2004-06-17 2005-12-23 Galderma Sa Composition de type emulsion inverse contenant du calcitrol et du 17-propionate de clobetasol, et ses utilisations en cosmetiques et en dermatologie
JP4608618B2 (ja) * 2004-07-02 2011-01-12 有限会社 エヌ・ピィ・アール ネイルアート用溶液
US20060062982A1 (en) * 2004-09-17 2006-03-23 Massachusetts Institute Of Technology Carbon-polymer electrochemical systems and methods of fabricating them using layer-by-layer technology
CA2498623A1 (en) * 2005-02-18 2006-08-18 Qlt Inc. Treatment of onychomycosis
WO2006111426A1 (en) * 2005-04-19 2006-10-26 Galderma S.A. Composition of film-forming solution type, comprising vitamin d or a derivative thereof and a corticosteroid, and use thereof in dermatology
FR2884419B1 (fr) * 2005-04-19 2007-06-22 Galderma Sa Composition de type solution filmogene comprenant de la vitamine d ou un de ses derives et un corticosteroide, et son utilisation en dermatologie
WO2006130510A2 (en) 2005-05-27 2006-12-07 Taro Pharmaceuticals U.S.A., Inc. Stable liquid desoximethasone compositions with reduced oxidized impurity
KR100803926B1 (ko) 2006-07-27 2008-02-15 주식회사 코리아나화장품 샌드프리 화장료 조성물
US20090317341A1 (en) * 2008-06-18 2009-12-24 Conopco, Inc., D/B/A Unilever Compositions for Lightening Skin Color
FR2937250B1 (fr) * 2008-10-21 2013-05-10 Fabre Pierre Dermo Cosmetique Solution filmogene a base d'uree pour le traitement du psorasis de l'ongle
SG10201912526TA (en) 2009-10-01 2020-02-27 Adare Pharmaceuticals Inc Orally administered corticosteroid compositions
WO2015034678A2 (en) 2013-09-06 2015-03-12 Aptalis Pharmatech, Inc. Corticosteroid containing orally disintegrating tablet compositions for eosinophilic esophagitis
TWI728172B (zh) 2016-08-18 2021-05-21 美商愛戴爾製藥股份有限公司 治療嗜伊紅性食道炎之方法
PL233616B1 (pl) 2017-08-10 2019-11-29 Podopharm Spolka Z Ograniczona Odpowiedzialnoscia Preparat do paznokci, dloni i stop oraz sposob wytwarzania tego preparatu
WO2024024520A1 (ja) * 2022-07-28 2024-02-01 花王株式会社 外用剤組成物

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3928261A (en) * 1973-05-17 1975-12-23 Minnesota Mining & Mfg Water removable film-forming compositions for topical application to skin
US3861932A (en) * 1973-12-13 1975-01-21 Revlon Stabilization of nitrocellulose
US3966924A (en) * 1974-11-13 1976-06-29 Allergan Pharmaceuticals Composition and method for treating psoriasis
US4179304A (en) * 1978-04-03 1979-12-18 Polychrome Corporation Finger nail lacquer
US4210633A (en) * 1978-10-20 1980-07-01 Eli Lilly And Company Flurandrenolide film formulation
US4250164A (en) * 1979-04-09 1981-02-10 Bernstein Joel E Method of treating psoriasis of the nails and composition
EP0247142B1 (en) * 1985-11-04 1993-01-07 Owen/Galderma Laboratories Inc. Film-forming, pharmaceutical vehicles for application of medicaments to nails, pharmaceutical compositions based on those vehicles, and methods of using same
DE3544983A1 (de) * 1985-12-19 1987-06-25 Hoechst Ag Antimykotisch wirksamer nagellack
DE3612305A1 (de) * 1986-04-11 1987-10-22 Roehm Pharma Gmbh Fluessige arzneiform zur therapie der psoriasis auf basis filmbildender polymere
US5091171B2 (en) * 1986-12-23 1997-07-15 Tristrata Inc Amphoteric compositions and polymeric forms of alpha hydroxyacids and their therapeutic use
DE3720147A1 (de) * 1987-06-16 1988-12-29 Hoechst Ag Antimykotisch wirksamer nagellack sowie verfahren zu dessen herstellung
US5093108A (en) * 1989-02-16 1992-03-03 Amalia, Inc. Quick-drying nail enamel compositions and method for coating a surface
CA2008775C (en) * 1989-02-24 1998-12-22 Alberto Ferro Nail lacquer
US5258186A (en) * 1989-03-10 1993-11-02 Yamanouchi Pharmaceutical Co., Ltd. Drug release controlling coating material for long acting formulations
HU219480B (hu) * 1991-05-23 2001-04-28 Novartis Ag. Eljárás gombás körömmegbetegségek ellen helyileg alkalmazható, allil-amin-származékot tartalmazó gyógyászati készítmények előállítására
DE19518262A1 (de) * 1995-05-18 1996-11-21 Hoechst Ag Die Verwendung von Glyceryltriacetat zur Behandlung von Onychomykosen
NZ267488A (en) * 1993-07-28 1997-09-22 Pfizer Topical psoriasis treatment composition comprising a film-forming agent
DK128494A (da) * 1994-11-08 1996-05-09 Edel K Seidenschnur Behandling af keratinøse og psoriatiske sygdomstilstande med neglelak indeholdende vitamin D metabolit, eller derivat, og/eller vitamin A derivat
DE19529085A1 (de) * 1995-08-08 1997-02-13 Christiane Dr Med Wurdel Nagellack zur Bekämpfung der Schuppenflechte im Nagelbereich
CA2248977A1 (en) * 1996-03-16 1997-09-25 Hoechst Aktiengesellschaft Topical formulations for the treatment of nail psoriasis
GB9609653D0 (en) 1996-05-09 1996-07-10 Applied Research Ars Holding N Method of assay
RO118174B1 (ro) * 1997-08-21 2003-03-28 Aventis Pharma Deutschland Gmbh Lac de unghii şi utilizarea acestuia

Also Published As

Publication number Publication date
HRP980458A2 (en) 1999-06-30
CN1155386C (zh) 2004-06-30
TW590776B (en) 2004-06-11
CN1209318A (zh) 1999-03-03
TR199801609A2 (xx) 1999-03-22
BG102696A (en) 1999-04-30
US20040071645A1 (en) 2004-04-15
DE59806343D1 (de) 2003-01-02
SI0913154T1 (en) 2003-04-30
HUP9801898A1 (hu) 1999-04-28
ES2186952T3 (es) 2003-05-16
US20010006625A1 (en) 2001-07-05
KR100610517B1 (ko) 2007-04-25
TR199801609A3 (tr) 1999-03-22
CZ263298A3 (cs) 1999-03-17
NO983818L (no) 1999-02-22
ZA987531B (en) 1999-02-22
US20020071815A1 (en) 2002-06-13
SK284218B6 (en) 2004-11-03
ID20731A (id) 1999-02-25
BR9803756A (pt) 2000-03-28
EP0913154A1 (de) 1999-05-06
RU2210354C2 (ru) 2003-08-20
RO118174B1 (ro) 2003-03-28
HUP9801898A3 (en) 2000-01-28
HK1018214A1 (en) 1999-12-17
DK0913154T3 (da) 2003-03-03
PT913154E (pt) 2003-04-30
HU9801898D0 (en) 1998-10-28
PL328122A1 (en) 1999-03-01
NO319391B1 (no) 2005-08-08
ATE227993T1 (de) 2002-12-15
SK114398A3 (en) 1999-03-12
CA2245637C (en) 2008-07-15
EP0913154B1 (de) 2002-11-20
UA51693C2 (uk) 2002-12-16
PL192342B1 (pl) 2006-10-31
HRP980458B1 (en) 2002-12-31
YU49492B (sh) 2006-08-17
CZ292344B6 (cs) 2003-09-17
YU34998A (sh) 2002-11-15
AU740615B2 (en) 2001-11-08
SG68072A1 (en) 1999-10-19
MY128558A (en) 2007-02-28
IL125854A0 (en) 1999-04-11
BG63270B1 (bg) 2001-08-31
IL125854A (en) 2004-02-19
US6352686B2 (en) 2002-03-05
NO983818D0 (no) 1998-08-20
KR19990023719A (ko) 1999-03-25
JPH11130679A (ja) 1999-05-18
CA2245637A1 (en) 1999-02-21
AU8085698A (en) 1999-03-04
NZ331443A (en) 1999-01-28
AR015933A1 (es) 2001-05-30

Similar Documents

Publication Publication Date Title
CO4960649A1 (es) Esmalte para unas que contiene al menos un glucocorticoide y procedimiento de fabricacion
Corren Intranasal corticosteroids for allergic rhinitis: how do different agents compare?
JP5699169B2 (ja) 少なくとも１つのビタミンｄまたは１つのビタミンｄアナログおよび少なくとも１つのコルチコステロイドを含有する局所用組成物
EP2214643B1 (en) Transdermal delivery system for hormones and steroids
KR100853436B1 (ko) 환자에게 피부병 약제를 투여하는 방법
Nast et al. German evidence-based guidelines for the treatment of psoriasis vulgaris (short version)
DK2915534T3 (en) Pharmaceutical composition for dermal use for the treatment of psoriasis comprising vitamin D and a corticosteroid
JP2018197259A5 (es)
HRP20161279T1 (hr) Kombinirani preparati s antagonistom citokina i ortikosteroidom
Castela et al. Topical corticosteroids in plaque psoriasis: a systematic review of efficacy and treatment modalities
JP2004512297A5 (es)
EP1465636A2 (en) Compositions and methods for enhancing corticosteriod delivery
Goossens et al. Reactions to corticosteroids: some new aspects regarding cross-sensitivity
JP2013542990A5 (es)
CN101505725A (zh) 包含含维生素D的化合物和皮质类固醇化合物的具有低pH相容性的稳定的药理学活性组合物
AR019321A1 (es) Composicion espumosa para el lavado y el tratamiento del cabello y/o del cuero cabelludo que contiene un principio activo, un tensioactivo anionico, untensioactivo anfotero y un agente propenetrante y su utilizacion para la elaboracion de un medicamento.
STOUGHTON The vasoconstrictor assay in bioequivalence testing: practical concerns and recent developments
Berbegal et al. Corticosteroid Hypersensitivity Studies in a Skin Allergy Unit
JP2004519451A5 (es)
US6300326B1 (en) Composition and method for control and treatment of cutaneous inflammation
Kerscher et al. Topical treatment with glucocorticoids
RU2007124549A (ru) Средство, усиливающее действие адренокортикоидов, содержащее аравийскую камедь
Thorburn et al. Topical corticosteroids and lesions of the oral mucosa
RU2010154665A (ru) Способ предотвращения использования кортикостероидов
Higashi Vasoconstrictor Assay of Proprietary Topical Corticosteroid Preparations in Japan